Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology at the earliest stage of some neurodegenerative disorders, but do not have the scalability needed for population screening. Therefore, a blood-based marker for such pathophysiology would have greater utility in a primary care setting and in eligibility screening for clinical trials. Rapid advances in ultra-sensitive assays have enabled the levels of pathological proteins to be measured in blood samples, but research has been predominantly focused on Alzheimer disease (AD). Nonetheless, proteins that were identified as potential blood-based biomarkers for AD, for example, amyloid-β, tau, phosphorylated tau and neurofilament light chain, are likely to be...
Alzheimer’s disease (AD) is the most common neurodegenerative disease among the elderly, affecting m...
Biomarker discovery and development for clinical research, diagnostics and therapy monitoring in cli...
New concepts about Alzheimer's disease (AD), considered as a clinical-biological entity, make essent...
Most research into blood-based biomarkers for neurodegenerative disorders has so far focused on Alzh...
Alzheimer's disease (AD) is a progressive neurodegenerative disease and the single commonest cause o...
For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent resul...
For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent resul...
Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public health chal...
Alzheimer's disease (AD) characterization has progressed from being indexed using clinical symptomat...
Biomarker discovery and development for clinical research, diagnostics and therapy monitoring in cli...
Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in the clinic ...
There is still a substantial unmet need for less invasive and lower-cost molecular biomarkers, namel...
Potential biomarkers for Alzheimer’s disease (AD) include amyloid β1–42 (Aβ1–42), t-Tau, p-Tau181, n...
The diagnostic guidelines of Alzheimer's disease (AD) have recently been updated to include brain im...
The past few years have seen an explosion in sensitive and specific assays for cerebrospinal fluid (...
Alzheimer’s disease (AD) is the most common neurodegenerative disease among the elderly, affecting m...
Biomarker discovery and development for clinical research, diagnostics and therapy monitoring in cli...
New concepts about Alzheimer's disease (AD), considered as a clinical-biological entity, make essent...
Most research into blood-based biomarkers for neurodegenerative disorders has so far focused on Alzh...
Alzheimer's disease (AD) is a progressive neurodegenerative disease and the single commonest cause o...
For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent resul...
For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent resul...
Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public health chal...
Alzheimer's disease (AD) characterization has progressed from being indexed using clinical symptomat...
Biomarker discovery and development for clinical research, diagnostics and therapy monitoring in cli...
Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in the clinic ...
There is still a substantial unmet need for less invasive and lower-cost molecular biomarkers, namel...
Potential biomarkers for Alzheimer’s disease (AD) include amyloid β1–42 (Aβ1–42), t-Tau, p-Tau181, n...
The diagnostic guidelines of Alzheimer's disease (AD) have recently been updated to include brain im...
The past few years have seen an explosion in sensitive and specific assays for cerebrospinal fluid (...
Alzheimer’s disease (AD) is the most common neurodegenerative disease among the elderly, affecting m...
Biomarker discovery and development for clinical research, diagnostics and therapy monitoring in cli...
New concepts about Alzheimer's disease (AD), considered as a clinical-biological entity, make essent...